Danaher Acquires Precision NanoSystems

Bruker Corporation Acquires NanoString Technologies Business

May 6, 2024

Medical Devices

Bruker Corporation has acquired substantially all assets of NanoString Technologies, Inc. through a court-supervised Chapter 11 asset sale for approximately $392.6 million in cash plus assumption of certain liabilities. The deal, announced April 2024 and closed in late April/early May 2024, brings NanoString's spatial biology and gene-expression product lines into Bruker to preserve customer access, product development, and jobs while expanding Bruker's life‑science instrumentation capabilities.

Second Sight Medical Products Completes Merger with Nano Precision Medical and Becomes Vivani Medical, Inc.

August 30, 2022

Biotechnology

Second Sight Medical Products completed its merger with Nano Precision Medical and changed its name to Vivani Medical, Inc., with the combined company trading on Nasdaq under the ticker VANI. The transaction brings approximately $55 million in cash to advance Nano Precision Medical's NanoPortal implant portfolio (including lead asset NPM-119) into clinical development and places Nano Precision CEO Dr. Adam Mendelsohn as CEO of the combined company.

Danaher Corporation Acquires Genedata AG

August 19, 2024

Software

Danaher Corporation has acquired Genedata AG, a Basel-based provider of software solutions for biopharmaceutical R&D, and will integrate the company into its Life Sciences segment. The acquisition expands Danaher’s R&D workflow capabilities by adding Genedata’s data-driven informatics and automation tools to accelerate drug discovery and development.

Medtronic Acquires Nano Surface Technology Assets from Nanovis

February 12, 2025

Medical Devices

Medtronic plc acquired certain nano surface technology assets and related IP rights from Columbia City, Indiana-based Nanovis to support development of next-generation PEEK interbody fusion devices. Financial terms were not disclosed; the deal transfers Nanovis’ bone-growth nanotechnology (including rights related to Sites Medical’s OsteoSync titanium pads) to Medtronic for integration into its spinal implant portfolio.

Element Materials Technology Acquires Nanosyn

October 11, 2021

Pharmaceuticals

Element Materials Technology acquired Nanosyn, a San Francisco Bay Area-based contract development and manufacturing organization (CDMO) focused on drug discovery and small-batch API manufacturing, to strengthen Element’s pharmaceuticals and biopharmaceutical services in North America. Nanosyn operates three Bay Area facilities and has a team of more than 75 scientists, and the deal expands Element’s end-to-end life sciences capabilities from discovery through clinical development and regulatory support.

Novo Nordisk Acquires Dicerna Pharmaceuticals

November 18, 2021

Biotechnology

Novo Nordisk agreed to acquire Dicerna Pharmaceuticals for $38.25 per share, representing an enterprise equity value of approximately $3.3 billion, to expand its RNAi capabilities. The acquisition builds on a 2019 research collaboration and brings Dicerna's GalXC RNAi platform and pipeline into Novo Nordisk to accelerate development of RNAi therapeutics across cardiometabolic, liver and rare disease indications. The tender offer completed in December 2021 and Dicerna is now a wholly owned subsidiary of Novo Nordisk.